Entering text into the input field will update the search result below

Achieve: Late-Stage Biotech Developing Vaping And Smoking Cessation Drugs

BiotechValley Insights profile picture
BiotechValley Insights


  • Positive Phase 2 ORCA-V1 trial results show cytisinicline's potential in helping users quit vaping, with an odds ratio of 2.6 compared to placebo, suggesting a strong case for FDA approval.
  • Cytisinicline demonstrated a favorable safety profile with no significant adverse events, which is crucial for a product targeting a wide population, including younger users of e-cigarettes.
  • The Phase 3 ORCA-3 trial's top-line outcomes, expected in Q2 2023, represent the next key catalyst for investors to watch closely.
  • Key risks include a short cash runway, potential dilution from public offerings, regulatory/clinical risks, and the need for a commercialization partnership with pharma.
Young man smoking marijuana joint beside woman in car

SimonSkafar/E+ via Getty Images

Update to thesis: Phase 2 e-cigarette trial data

As we anticipated, Achieve Life Sciences (NASDAQ:ACHV) has recently released positive top-line findings from its Phase 2 ORCA-V1 clinical trial, and the stock is up 200%+ this year.

We would like to

This article was written by

BiotechValley Insights profile picture
We publish unbiased long/short trade ideas. Please follow our Twitter page: https://twitter.com/biotechvalley_i

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Biotechvalley Insights (BTVI) is not a registered investment advisor, and articles are not targeted toward retail investors. The content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in our articles or comments constitutes a solicitation, recommendation, endorsement, or offer by Biotechvalley Insights or any third-party service provider to buy or sell any securities or other financial instruments in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. The research and reports made available by BTVI reflect and express the opinion of the applicable BTVI entity as of the time of the report only. Reports are based on generally-available information, field research, inferences, and deductions through the applicable due diligence and analytical process. BTVI may use resources from brokerage reports, corporate IR, and KOL/expert interviews that may have a conflict of interest with the company/assets that BTVI covers. To the best of the applicable BTVI's ability and belief, all information contained herein is accurate and reliable, is not material non-public information, and has been obtained from public sources that the applicable BTVI entity believes to be accurate and reliable. However, such information is presented “as is” without warranty of any kind, whether express or implied. With respect to their respective research reports, BTVI makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information or with regard to the results to be obtained from its use. Further, any analysis/comment contains a very large measure of analysis and opinion. All expressions of opinion are subject to change without notice, and BTVI does not undertake to update or supplement any reports or any of the information, analysis, and opinion contained in them.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (2)

Positive results reported today for the Phase 3 study and stock is way down. I suppose we can call this profit taking on good news.
Geromar profile picture
Fda approval coming
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.